<DOC>
	<DOC>NCT02092935</DOC>
	<brief_summary>The purpose of this research study is to evaluate the safety and effectiveness of a new oral antibiotic called SMT19969 in treating C. difficile Infection (CDI).</brief_summary>
	<brief_title>A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Informed consent Clinical diagnosis of CDAD plus laboratory diagnostic test No more than 24 hrs antimicrobial treatment for current CDAD episode No more than 3 episodes of CDAD in prior 12 months No previous episode of CDAD within 30 days of study enrollment Female subjects of childbearing potential must use adequate contraception Lifethreatening or fulminant colitis Concurrent use of antibiotics or any other treatments for CDAD History of inflammatory bowel disease (ulcerative colitis, Crohn's disease) Participation in other Clinical research studies within one month of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>CDAD</keyword>
	<keyword>Clostridium Difficile</keyword>
</DOC>